Table of Contents

1 Study Coverage

• 1.1 Diabetes Drug Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Diabetes Drug Market Size Growth Rate by Product
  • 1.4.2 Insulin
  • 1.4.3 Sensitizers
  • 1.4.4 SGLT-2 Inhibitors
  • 1.4.5 Alpha-glucosidase Inhibitors
  • 1.4.6 Secretagogues
  • 1.4.7 Peptide Analogs
  • 1.4.8 Others
• 1.5 Market by End User
  • 1.5.1 Global Diabetes Drug Market Size Growth Rate by End User
  • 1.5.2 Hospital
  • 1.5.3 Clinic
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Diabetes Drug Market Size
  • 2.1.1 Global Diabetes Drug Revenue 2014-2025
  • 2.1.2 Global Diabetes Drug Sales 2014-2025
• 2.2 Diabetes Drug Growth Rate by Regions
  • 2.2.1 Global Diabetes Drug Sales by Regions
  • 2.2.2 Global Diabetes Drug Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Diabetes Drug Sales by Manufacturers
  • 3.1.1 Diabetes Drug Sales by Manufacturers
  • 3.1.2 Diabetes Drug Sales Market Share by Manufacturers
  • 3.1.3 Global Diabetes Drug Market Concentration Ratio (CR5 and HHI)
• 3.2 Diabetes Drug Revenue by Manufacturers
  • 3.2.1 Diabetes Drug Revenue by Manufacturers (2014-2019)
  • 3.2.2 Diabetes Drug Revenue Share by Manufacturers (2014-2019)
• 3.3 Diabetes Drug Price by Manufacturers
• 3.4 Diabetes Drug Manufacturing Base Distribution, Product Types
  • 3.4.1 Diabetes Drug Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Diabetes Drug Product Type
  • 3.4.3 Date of International Manufacturers Enter into Diabetes Drug Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Diabetes Drug Sales by Product
• 4.2 Global Diabetes Drug Revenue by Product
• 4.3 Diabetes Drug Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Diabetes Drug Breakdown Data by End User

6 North America

• 6.1 North America Diabetes Drug by Countries
  • 6.1.1 North America Diabetes Drug Sales by Countries
  • 6.1.2 North America Diabetes Drug Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Diabetes Drug by Product
• 6.3 North America Diabetes Drug by End User

7 Europe

• 7.1 Europe Diabetes Drug by Countries
  • 7.1.1 Europe Diabetes Drug Sales by Countries
  • 7.1.2 Europe Diabetes Drug Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Diabetes Drug by Product
• 7.3 Europe Diabetes Drug by End User

8 Asia Pacific

• 8.1 Asia Pacific Diabetes Drug by Countries
  • 8.1.1 Asia Pacific Diabetes Drug Sales by Countries
  • 8.1.2 Asia Pacific Diabetes Drug Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Diabetes Drug by Product
• 8.3 Asia Pacific Diabetes Drug by End User

9 Central & South America

• 9.1 Central & South America Diabetes Drug by Countries
  • 9.1.1 Central & South America Diabetes Drug Sales by Countries
  • 9.1.2 Central & South America Diabetes Drug Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Diabetes Drug by Product
• 9.3 Central & South America Diabetes Drug by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Diabetes Drug by Countries
  • 10.1.1 Middle East and Africa Diabetes Drug Sales by Countries
  • 10.1.2 Middle East and Africa Diabetes Drug Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Diabetes Drug by Product
• 10.3 Middle East and Africa Diabetes Drug by End User

11 Company Profiles

• 11.1 Eli Lilly
  • 11.1.1 Eli Lilly Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Eli Lilly Diabetes Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Eli Lilly Diabetes Drug Products Offered
  • 11.1.5 Eli Lilly Recent Development
• 11.2 Novo Nordisk
  • 11.2.1 Novo Nordisk Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Novo Nordisk Diabetes Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Novo Nordisk Diabetes Drug Products Offered
  • 11.2.5 Novo Nordisk Recent Development
• 11.3 Abbott
  • 11.3.1 Abbott Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Abbott Diabetes Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Abbott Diabetes Drug Products Offered
  • 11.3.5 Abbott Recent Development
• 11.4 AstraZeneca
  • 11.4.1 AstraZeneca Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 AstraZeneca Diabetes Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 AstraZeneca Diabetes Drug Products Offered
  • 11.4.5 AstraZeneca Recent Development
• 11.5 Biocon
  • 11.5.1 Biocon Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Biocon Diabetes Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Biocon Diabetes Drug Products Offered
  • 11.5.5 Biocon Recent Development
• 11.6 Sunpharma
  • 11.6.1 Sunpharma Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Sunpharma Diabetes Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Sunpharma Diabetes Drug Products Offered
  • 11.6.5 Sunpharma Recent Development
• 11.7 Sanofi
  • 11.7.1 Sanofi Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Sanofi Diabetes Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Sanofi Diabetes Drug Products Offered
  • 11.7.5 Sanofi Recent Development
• 11.8 Novartis
  • 11.8.1 Novartis Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Novartis Diabetes Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Novartis Diabetes Drug Products Offered
  • 11.8.5 Novartis Recent Development
• 11.9 Merck
  • 11.9.1 Merck Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Merck Diabetes Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Merck Diabetes Drug Products Offered
  • 11.9.5 Merck Recent Development
• 11.10 Pfizer
  • 11.10.1 Pfizer Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Pfizer Diabetes Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Pfizer Diabetes Drug Products Offered
  • 11.10.5 Pfizer Recent Development
• 11.11 Daiichi Sankyo
• 11.12 Boehringer Ingelheim
• 11.13 Akros Pharma
• 11.14 Amgen
• 11.15 Adocia
• 11.16 Peptron
• 11.17 Takeda

12 Future Forecast

• 12.1 Diabetes Drug Market Forecast by Regions
  • 12.1.1 Global Diabetes Drug Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Diabetes Drug Revenue Forecast by Regions 2019-2025
• 12.2 Diabetes Drug Market Forecast by Product
  • 12.2.1 Global Diabetes Drug Sales Forecast by Product 2019-2025
  • 12.2.2 Global Diabetes Drug Revenue Forecast by Product 2019-2025
• 12.3 Diabetes Drug Market Forecast by End User
• 12.4 North America Diabetes Drug Forecast
• 12.5 Europe Diabetes Drug Forecast
• 12.6 Asia Pacific Diabetes Drug Forecast
• 12.7 Central & South America Diabetes Drug Forecast
• 12.8 Middle East and Africa Diabetes Drug Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Diabetes Drug Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two type of diabetes namely type-1 diabetes and type-2 diabetes. During last decade there is a tremendous increase in the number of diabetic population.
The analysis shows human insulins and analogues dominated the antidiabetics market in 2017.
The global Diabetes Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Diabetes Drug market based on company, product type, end user and key regions.

This report studies the global market size of Diabetes Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Diabetes Drug in these regions.
This research report categorizes the global Diabetes Drug market by top players/brands, region, type and end user. This report also studies the global Diabetes Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Eli Lilly
Novo Nordisk
Abbott
AstraZeneca
Biocon
Sunpharma
Sanofi
Novartis
Merck
Pfizer
Daiichi Sankyo
Boehringer Ingelheim
Akros Pharma
Amgen
Adocia
Peptron
Takeda

Market size by Product
Insulin
Sensitizers
SGLT-2 Inhibitors
Alpha-glucosidase Inhibitors
Secretagogues
Peptide Analogs
Others
Market size by End User
Hospital
Clinic
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Diabetes Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Diabetes Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Diabetes Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Diabetes Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Diabetes Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Diabetes Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.